予測期間中、網膜の健康市場は7.01%のCAGR で成長すると予想されます。「網膜」という用語は、眼に入る光を脳が画像に処理できる電気信号に変換する、眼の後ろにある薄い層を指します。視覚障害や失明の予防は、健康な網膜にかかっています。世界中で網膜疾患の頻度が増加し、戦略的取組みが増加していることが、網膜の健康に関する世界市場の成長を促進していると考えられます。さらに、網膜疾患の認識を高めるために行動を起こす公的および私的なグループが増加しています。ただし、網膜疾患に関する知識の欠如が市場の拡大を妨げる可能性があります。
世界の網膜の健康市場は、網膜色素変性症、糖尿病性網膜症、加齢黄斑変性症 (AMD)、網膜剥離などの発症数の増加によって大きく拡大すると予想されます。さらに、特にCOVID-19の流行中に、近視の有病率と視力障害の症例が増加したため、市場は成長しています。これは、自宅で仕事をしているときに画面を使用して仮想会議に参加する人が増えているためです。これにより、近視の有病率が増加し、AMD を含む他の進行性の眼疾患を発症する可能性が高まっています。 さらに、網膜生物製剤に関する消費者の知識が高まることが、市場の拡大を促します。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING PREVALENCE OF RETINAL DISEASES ACROSS THE GLOBE
4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING RETINAL DISEASES
4.4 OPPORTUNITY
4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING RETINAL DISEASES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE RETINA HEALTH MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON MARKET PLAYERS
5.3.4 IMPACT ON DEMAND
6 GLOBAL RETINA HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 THERAPY
6.3.1 GENE THERAPY
6.3.2 NUTRITION THERAPY
6.3.3 OTHERS
6.4 SURGERY
7 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION
7.1 OVERVIEW
7.2 AGE-RELATED MACULAR DEGENERATION
7.3 DIABETIC RETINOPATHY
7.4 INHERITED RETINAL DISEASES
7.5 RETINOBLASTOMA
7.6 OTHERS
8 GLOBAL RETINA HEALTH MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL RETINA HEALTH MARKET
9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL RETINA HEALTH MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
9.6.2 MERGER & ACQUISITIONS
9.6.3 EXPANSION
9.6.4 AGREEMENT/MARKETING STRATEGIES
9.7 FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILES
10.1 NOVARTIS AG
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 SPARK THERAPEUTICS, INC.
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS/SERVICES OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIES
10.3 GENSIGHT BIOLOGICS
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS/SERVICES OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 ALLERGAN PLC (SUBSIDIARY OF ABBVIE INC.)
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS/SERVICES OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 OXFORD BIOMEDICA PLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS/SERVICES OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 HEMERA BIOSCIENCES LLC
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS/SERVICES OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 SANTEN PHARMACEUTICALS INC.
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 REGENXBIO INC.
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 MEIRAGTX LIMITED
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC)
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
